MSC Nordics compared deals and fundraising conducted during the first half of 2021 and 2022 and found that even though the macroeconomic situation has become more challenging since the beginning of 2021, there are still significant deals being made within ATMPs!
Although financing and M&A activity is decreasing, licensing is going strong with an increase in deal value by 216% only a slight decrease in deal count.
Figure 1: Source Nature Biopharma Dealmakers. Illustrating
strategic alliances deal trends of H1 2021 and H1 2022.
If you want to get a better view on ATMP deals and fundraising, buy the December issue or check the article out here: https://www.nature.com/articles/d43747-022-00247-7